New combo therapy shows promise for Hard-to-Treat bile duct cancer
NCT ID NCT07466238
First seen Mar 18, 2026 · Last updated May 13, 2026 · Updated 8 times
Summary
This study tests a treatment for biliary tract cancer (a rare and aggressive cancer of the bile ducts or gallbladder) that cannot be removed by surgery. The approach combines hepatic arterial infusion chemotherapy (HAIC), which delivers high-dose chemo directly to the liver, with standard systemic therapy. The goal is to shrink tumors enough to allow surgery or improve survival. About 40 adults with newly diagnosed, advanced biliary tract cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University Cancer Hospital
NOT_YET_RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.